TALi appoints new CEO
TALi Health is delighted to announce that Dr Mary Beth Brinson has been appointed as the CEO of TALi Health.
Read moreWe are 100% invested in TALi Health who are developing evidence-based tools to measure, assess and improve attention.
TALi has built platform technology, with the initial applications targeting cognitive attention skills during early childhood. The first to market attention screening ('DETECT') and training ('TRAIN') programs are complementary to existing diagnosis and therapy placing TALi at the forefront of early intervention for attention related conditions.
A continuous innovation focus sees TALi deliver ongoing product developments in this space, which are underpinned by a core research program exploring additional applications.
TALi Health is delighted to announce that Dr Mary Beth Brinson has been appointed as the CEO of TALi Health.
Read moreTALi partner Akili Interactive has been named one of the 10 Most Innovative Companies in Medicines and Therapeutics for 2022 by Fast Company magazine in the United States.
Read moreWe’re pleased to say we’ve been granted a patent for our attention assessment and training program in New Zealand. This new patent joins those we have in the United States, Australia and Japan, with other jurisdictions ...
Read more